Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
23
ZRSEF Quote, Financials, Valuation and Earnings
Last price:
$7.45
Seasonality move
:
-27.52%
Day range:
$7.45 - $7.45
52-week range:
$7.45 - $16.22
Dividend yield:
0%
P/E ratio:
11.59x
P/S ratio:
0.12x
P/B ratio:
0.60x
Volume:
10
Avg. volume:
--
1-year change:
-54.04%
Market cap:
$362.3M
Revenue:
$1.4B
EPS (TTM):
-$9.29
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ZRSEF
DocMorris Ltd.
|
-- | -- | -- | -- | -- |
|
BPMUF
Basilea Pharmaceutica AG
|
$154.5M | -- | -- | -- | -- |
|
CSBTF
Kuros Biosciences Ltd.
|
-- | -- | -- | -- | -- |
|
ELVAF
EvoNext Holdings SA
|
-- | -- | -- | -- | -- |
|
ONC
BeOne Medicines Ltd.
|
$1.6B | $1.32 | 28.64% | 7066.67% | $408.32 |
|
SPHDF
Santhera Pharmaceuticals Holding AG
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ZRSEF
DocMorris Ltd.
|
$7.45 | -- | $362.3M | 11.59x | $0.00 | 0% | 0.12x |
|
BPMUF
Basilea Pharmaceutica AG
|
$71.00 | -- | $871.3M | 19.33x | $0.00 | 0% | 3.46x |
|
CSBTF
Kuros Biosciences Ltd.
|
$27.79 | -- | $1.1B | 451.14x | $0.00 | 0% | 7.47x |
|
ELVAF
EvoNext Holdings SA
|
$1.1700 | -- | $8.4M | 5.90x | $0.00 | 0% | 0.61x |
|
ONC
BeOne Medicines Ltd.
|
$310.79 | $408.32 | $34.8B | 124.20x | $0.00 | 0% | 6.63x |
|
SPHDF
Santhera Pharmaceuticals Holding AG
|
$19.60 | -- | $254.2M | 1.45x | $0.00 | 0% | 4.43x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ZRSEF
DocMorris Ltd.
|
45.66% | -1.301 | 112.18% | 1.49x |
|
BPMUF
Basilea Pharmaceutica AG
|
85.07% | 1.032 | -- | 2.96x |
|
CSBTF
Kuros Biosciences Ltd.
|
-- | -0.122 | -- | 1.61x |
|
ELVAF
EvoNext Holdings SA
|
-- | 0.069 | -- | -- |
|
ONC
BeOne Medicines Ltd.
|
31.44% | 0.769 | 5.94% | 2.98x |
|
SPHDF
Santhera Pharmaceuticals Holding AG
|
33% | -1.767 | -- | 0.51x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ZRSEF
DocMorris Ltd.
|
$29.1M | -$26.7M | -13.54% | -24.63% | -- | -- |
|
BPMUF
Basilea Pharmaceutica AG
|
-- | -- | -0.84% | -15.42% | -- | -- |
|
CSBTF
Kuros Biosciences Ltd.
|
-- | -- | -6.35% | -6.35% | -- | -- |
|
ELVAF
EvoNext Holdings SA
|
-- | -- | -- | -- | -- | -- |
|
ONC
BeOne Medicines Ltd.
|
$1.3B | $185.8M | 5.51% | 7.54% | 12.35% | $381.2M |
|
SPHDF
Santhera Pharmaceuticals Holding AG
|
-- | -- | 123.12% | 276.68% | -- | -- |
DocMorris Ltd. vs. Competitors
-
Which has Higher Returns ZRSEF or BPMUF?
Basilea Pharmaceutica AG has a net margin of -- compared to DocMorris Ltd.'s net margin of --. DocMorris Ltd.'s return on equity of -24.63% beat Basilea Pharmaceutica AG's return on equity of -15.42%.
Company Gross Margin Earnings Per Share Invested Capital ZRSEFDocMorris Ltd.-- -$1.28 $692.8M BPMUFBasilea Pharmaceutica AG-- -- $125.1M -
What do Analysts Say About ZRSEF or BPMUF?
DocMorris Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Basilea Pharmaceutica AG has an analysts' consensus of -- which suggests that it could fall by --. Given that DocMorris Ltd. has higher upside potential than Basilea Pharmaceutica AG, analysts believe DocMorris Ltd. is more attractive than Basilea Pharmaceutica AG.
Company Buy Ratings Hold Ratings Sell Ratings ZRSEFDocMorris Ltd.0 0 0 BPMUFBasilea Pharmaceutica AG0 0 0 -
Is ZRSEF or BPMUF More Risky?
DocMorris Ltd. has a beta of 0.219, which suggesting that the stock is 78.12% less volatile than S&P 500. In comparison Basilea Pharmaceutica AG has a beta of 0.366, suggesting its less volatile than the S&P 500 by 63.449%.
-
Which is a Better Dividend Stock ZRSEF or BPMUF?
DocMorris Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Basilea Pharmaceutica AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DocMorris Ltd. pays -- of its earnings as a dividend. Basilea Pharmaceutica AG pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ZRSEF or BPMUF?
DocMorris Ltd. quarterly revenues are $315.8M, which are larger than Basilea Pharmaceutica AG quarterly revenues of --. DocMorris Ltd.'s net income of -$44M is higher than Basilea Pharmaceutica AG's net income of --. Notably, DocMorris Ltd.'s price-to-earnings ratio is 11.59x while Basilea Pharmaceutica AG's PE ratio is 19.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DocMorris Ltd. is 0.12x versus 3.46x for Basilea Pharmaceutica AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZRSEFDocMorris Ltd.0.12x 11.59x $315.8M -$44M BPMUFBasilea Pharmaceutica AG3.46x 19.33x -- --
-
Which has Higher Returns ZRSEF or CSBTF?
Kuros Biosciences Ltd. has a net margin of -- compared to DocMorris Ltd.'s net margin of --. DocMorris Ltd.'s return on equity of -24.63% beat Kuros Biosciences Ltd.'s return on equity of -6.35%.
Company Gross Margin Earnings Per Share Invested Capital ZRSEFDocMorris Ltd.-- -$1.28 $692.8M CSBTFKuros Biosciences Ltd.-- -- $65M -
What do Analysts Say About ZRSEF or CSBTF?
DocMorris Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Kuros Biosciences Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that DocMorris Ltd. has higher upside potential than Kuros Biosciences Ltd., analysts believe DocMorris Ltd. is more attractive than Kuros Biosciences Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ZRSEFDocMorris Ltd.0 0 0 CSBTFKuros Biosciences Ltd.0 0 0 -
Is ZRSEF or CSBTF More Risky?
DocMorris Ltd. has a beta of 0.219, which suggesting that the stock is 78.12% less volatile than S&P 500. In comparison Kuros Biosciences Ltd. has a beta of 1.022, suggesting its more volatile than the S&P 500 by 2.244%.
-
Which is a Better Dividend Stock ZRSEF or CSBTF?
DocMorris Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kuros Biosciences Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DocMorris Ltd. pays -- of its earnings as a dividend. Kuros Biosciences Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ZRSEF or CSBTF?
DocMorris Ltd. quarterly revenues are $315.8M, which are larger than Kuros Biosciences Ltd. quarterly revenues of --. DocMorris Ltd.'s net income of -$44M is higher than Kuros Biosciences Ltd.'s net income of --. Notably, DocMorris Ltd.'s price-to-earnings ratio is 11.59x while Kuros Biosciences Ltd.'s PE ratio is 451.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DocMorris Ltd. is 0.12x versus 7.47x for Kuros Biosciences Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZRSEFDocMorris Ltd.0.12x 11.59x $315.8M -$44M CSBTFKuros Biosciences Ltd.7.47x 451.14x -- --
-
Which has Higher Returns ZRSEF or ELVAF?
EvoNext Holdings SA has a net margin of -- compared to DocMorris Ltd.'s net margin of --. DocMorris Ltd.'s return on equity of -24.63% beat EvoNext Holdings SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ZRSEFDocMorris Ltd.-- -$1.28 $692.8M ELVAFEvoNext Holdings SA-- -- -- -
What do Analysts Say About ZRSEF or ELVAF?
DocMorris Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand EvoNext Holdings SA has an analysts' consensus of -- which suggests that it could fall by --. Given that DocMorris Ltd. has higher upside potential than EvoNext Holdings SA, analysts believe DocMorris Ltd. is more attractive than EvoNext Holdings SA.
Company Buy Ratings Hold Ratings Sell Ratings ZRSEFDocMorris Ltd.0 0 0 ELVAFEvoNext Holdings SA0 0 0 -
Is ZRSEF or ELVAF More Risky?
DocMorris Ltd. has a beta of 0.219, which suggesting that the stock is 78.12% less volatile than S&P 500. In comparison EvoNext Holdings SA has a beta of -34.970, suggesting its less volatile than the S&P 500 by 3597.022%.
-
Which is a Better Dividend Stock ZRSEF or ELVAF?
DocMorris Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EvoNext Holdings SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DocMorris Ltd. pays -- of its earnings as a dividend. EvoNext Holdings SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ZRSEF or ELVAF?
DocMorris Ltd. quarterly revenues are $315.8M, which are larger than EvoNext Holdings SA quarterly revenues of --. DocMorris Ltd.'s net income of -$44M is higher than EvoNext Holdings SA's net income of --. Notably, DocMorris Ltd.'s price-to-earnings ratio is 11.59x while EvoNext Holdings SA's PE ratio is 5.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DocMorris Ltd. is 0.12x versus 0.61x for EvoNext Holdings SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZRSEFDocMorris Ltd.0.12x 11.59x $315.8M -$44M ELVAFEvoNext Holdings SA0.61x 5.90x -- --
-
Which has Higher Returns ZRSEF or ONC?
BeOne Medicines Ltd. has a net margin of -- compared to DocMorris Ltd.'s net margin of 4.44%. DocMorris Ltd.'s return on equity of -24.63% beat BeOne Medicines Ltd.'s return on equity of 7.54%.
Company Gross Margin Earnings Per Share Invested Capital ZRSEFDocMorris Ltd.-- -$1.28 $692.8M ONCBeOne Medicines Ltd.88.43% $0.58 $6.4B -
What do Analysts Say About ZRSEF or ONC?
DocMorris Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand BeOne Medicines Ltd. has an analysts' consensus of $408.32 which suggests that it could grow by 31.38%. Given that BeOne Medicines Ltd. has higher upside potential than DocMorris Ltd., analysts believe BeOne Medicines Ltd. is more attractive than DocMorris Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ZRSEFDocMorris Ltd.0 0 0 ONCBeOne Medicines Ltd.17 2 0 -
Is ZRSEF or ONC More Risky?
DocMorris Ltd. has a beta of 0.219, which suggesting that the stock is 78.12% less volatile than S&P 500. In comparison BeOne Medicines Ltd. has a beta of 0.533, suggesting its less volatile than the S&P 500 by 46.676%.
-
Which is a Better Dividend Stock ZRSEF or ONC?
DocMorris Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BeOne Medicines Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DocMorris Ltd. pays -- of its earnings as a dividend. BeOne Medicines Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ZRSEF or ONC?
DocMorris Ltd. quarterly revenues are $315.8M, which are smaller than BeOne Medicines Ltd. quarterly revenues of $1.5B. DocMorris Ltd.'s net income of -$44M is lower than BeOne Medicines Ltd.'s net income of $66.8M. Notably, DocMorris Ltd.'s price-to-earnings ratio is 11.59x while BeOne Medicines Ltd.'s PE ratio is 124.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DocMorris Ltd. is 0.12x versus 6.63x for BeOne Medicines Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZRSEFDocMorris Ltd.0.12x 11.59x $315.8M -$44M ONCBeOne Medicines Ltd.6.63x 124.20x $1.5B $66.8M
-
Which has Higher Returns ZRSEF or SPHDF?
Santhera Pharmaceuticals Holding AG has a net margin of -- compared to DocMorris Ltd.'s net margin of --. DocMorris Ltd.'s return on equity of -24.63% beat Santhera Pharmaceuticals Holding AG's return on equity of 276.68%.
Company Gross Margin Earnings Per Share Invested Capital ZRSEFDocMorris Ltd.-- -$1.28 $692.8M SPHDFSanthera Pharmaceuticals Holding AG-- -- $79.8M -
What do Analysts Say About ZRSEF or SPHDF?
DocMorris Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Santhera Pharmaceuticals Holding AG has an analysts' consensus of -- which suggests that it could fall by --. Given that DocMorris Ltd. has higher upside potential than Santhera Pharmaceuticals Holding AG, analysts believe DocMorris Ltd. is more attractive than Santhera Pharmaceuticals Holding AG.
Company Buy Ratings Hold Ratings Sell Ratings ZRSEFDocMorris Ltd.0 0 0 SPHDFSanthera Pharmaceuticals Holding AG0 0 0 -
Is ZRSEF or SPHDF More Risky?
DocMorris Ltd. has a beta of 0.219, which suggesting that the stock is 78.12% less volatile than S&P 500. In comparison Santhera Pharmaceuticals Holding AG has a beta of -0.778, suggesting its less volatile than the S&P 500 by 177.839%.
-
Which is a Better Dividend Stock ZRSEF or SPHDF?
DocMorris Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Santhera Pharmaceuticals Holding AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DocMorris Ltd. pays -- of its earnings as a dividend. Santhera Pharmaceuticals Holding AG pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ZRSEF or SPHDF?
DocMorris Ltd. quarterly revenues are $315.8M, which are larger than Santhera Pharmaceuticals Holding AG quarterly revenues of --. DocMorris Ltd.'s net income of -$44M is higher than Santhera Pharmaceuticals Holding AG's net income of --. Notably, DocMorris Ltd.'s price-to-earnings ratio is 11.59x while Santhera Pharmaceuticals Holding AG's PE ratio is 1.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DocMorris Ltd. is 0.12x versus 4.43x for Santhera Pharmaceuticals Holding AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZRSEFDocMorris Ltd.0.12x 11.59x $315.8M -$44M SPHDFSanthera Pharmaceuticals Holding AG4.43x 1.45x -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 4
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 4
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 4
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
